An assay which measures the activity of 14 genes in lung cancer tumors can accurately predict who will respond well to surgery and who will probably die within five years, researchers from the University of California, San Francisco, reported in The Lancet. 80% of lung cancer patients have NSCLC (non-small-cell lung cancer) - their long term prognosis is poor, even after surgical interventions ...